Rekombinanter TIM3 Antikörper (AA 1-200)
Kurzübersicht für Rekombinanter TIM3 Antikörper (AA 1-200) (ABIN7868512)
Target
Alle TIM3 (TIM 3) Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
Klon
-
-
Bindungsspezifität
- AA 1-200
-
Verwendungszweck
- TIM-3 Antibody / HAVCR2 (azide and preservative free)
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- A recombinant fragment of human TIM3 protein (within amino acids 1-200) was used as the immunogen for the TIM-3 antibody.
-
Isotyp
- IgG, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the TIM-3 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Konservierungsmittel
- Azide free
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot the TIM-3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))
-
Andere Bezeichnung
- TIM-3
-
Hintergrund
- TIMs are type I transmembrane glycoproteins with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk. TIM-3 is expressed on the surface of effector T cells (CD4+ Th1 and CD8+ Tc1) but not on helper T cells (CD4+ Th2 and CD8+ Tc2). In chronic inflammation, autoimmune disorders, and some cancers, TIM-3 is upregulated on several other hematopoietic cell types. The Ig domain of TIM-3 interacts with a ligand on resting but not activated Th1 and Th2 cells. The glycosylated Ig domain of TIM-3 binds cell-associated galectin-9. This induces TIM-3 Tyr phosphorylation and pro-apoptotic signaling. TIM-3 functions as a negative regulator of Th1 cell activity. Its blockade results in increased IFN-gamma production, Th1 cell proliferation and cytotoxicity, regulatory T cell development, and increases in macrophage and neutrophil infiltration into sites of inflammation.
-
UniProt
- Q8TDQ0
-
Pathways
- Regulation of Lipid Metabolism by PPARalpha, Cancer Immune Checkpoints
Target
-